It is considered to expand the database and for this purpose there was a survey among the members about the priority of the possible additional information suche as Volume information, MEA, further price regulated products or Medical devices should and can be included in the database. The survey is still ongoing.
We are happy to announce that the 4th Stakeholder Dialogue Platform took place on 11 May 2021 with again very interesting inputs form DG SANTE, EFPIA, Medicines for Europe and OECD. Also, the Euripid Executive Committee presented their Ideas regarding access to medicinal products for European citizens.
The minutes and the presentations can be obtain from the Euripid network on the EU Health Policy Platform.
Please kindly enlist there if you not have done so yet. Please note: you will need your Transparency Registry number.
Finally the time has come and our official website is online. You can find all necessary information regarding the EURIPID project on this website. It should give an overview of the organization and the content of the project. The new website includes a newsletter function also. This newsletter will contain news from and beyond our project. It’s best to register now!
A recent survey among Euripid members confirmed their interest in sharing not only concrete price information but also information on the application of Managed Entry Agreements for individual products. Currently, 13 countries share information on MEAs for all or selected products. Another priority that was recently confirmed by members is the provision of volume information. Since January 2021, eleven countries share this information on the platform, partly dating back to 2015. The Secretariat is working on integrating information from a few more countries.
Further priorities of members include information on prices of non-reimbursed medicines or their patent status.
Also all but one respondent confirmed that they are either satisfied or very satisfied with the current form of the database.
Adopted on 25 November 2020, the Pharmaceutical Strategy for Europe aims at creating a future proof regulatory framework and at supporting industry in promoting research and technologies that actually reach patients in order to fulfil their therapeutic needs while addressing market failures.
The 3rd Fair Pricing Forum took place online from 13-22 April 2021 and focused again on improving access to medicines and health products through fair pricing, following the inaugural forum held in the Netherlands in 2017 (10–11 May) and the second forum in South Africa in 2019 (11-13 April). WHO invited the Euripid Collaboration to present our work. The presentation gives an overview of the collaboration and the project and outlines Euripid activities in improving access to medicines. An important information is that all countries from the WHO Euro Region may apply for membership.
In the light of the WHA resolution in 2019 on improving transparency in the medicines’ market, the EURIPID Executive Committee launched a survey to explore feasible options to foster information exchange and cross-country collaboration in this field.
The survey focused on high-cost and on-patent medicines, for which the sharing of price information is potentially more relevant.
The result were presented by the Italian Medicines Agency AIFA in September 2020.
